# ADVM-022 Intravitreal Gene Therapy for DME

> **NCT04418427** · PHASE2 · COMPLETED · sponsor: **Adverum Biotechnologies, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Diabetic Macular Edema
- Diabetic Retinopathy

## Interventions

- **BIOLOGICAL:** 6E11 vg/eye of ADVM-022
- **BIOLOGICAL:** 2E11 vg/eye of ADVM-022
- **BIOLOGICAL:** Aflibercept

## Key facts

- **NCT ID:** NCT04418427
- **Lead sponsor:** Adverum Biotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-28
- **Primary completion:** 2022-11-22
- **Final completion:** 2023-06-14
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04418427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04418427, "ADVM-022 Intravitreal Gene Therapy for DME". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04418427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*